Walder Wyss with dsm-firmenich on Pentapharm sale
Walder Wyss advised dsm-firmenich on the sale of Pentapharm and its Brazilian sister company Pentapharm do Brasil Comércio e Exportação to Orlando Capital V.
Founded in 1948 and headquartered in Aesch, Pentapharm is a provider of biological active ingredients for pharmaceutical and diagnostic applications, with a specific focus in the field of hemostasis.
The Walder Wyss team
Managing associate Michelle Bruni (corporate/M&A and tax, pictured) led the Walder Wyss team on the matter, working alongside partner Alexander Gutmans (corporate/M&A) and senior associate Simon Olstein (corporate/M&A).